Compare SLGN & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLGN | MMED |
|---|---|---|
| Founded | 1987 | 1983 |
| Country | United States | United States |
| Employees | N/A | 2800 |
| Industry | Containers/Packaging | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.3B |
| IPO Year | 1994 | 2026 |
| Metric | SLGN | MMED |
|---|---|---|
| Price | $40.48 | $18.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $52.78 | $22.56 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 04-29-2026 | 06-03-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $4,489,927,000.00 | N/A |
| Revenue This Year | $4.99 | $15.99 |
| Revenue Next Year | $2.20 | $10.00 |
| P/E Ratio | $68.57 | ★ N/A |
| Revenue Growth | ★ 0.92 | N/A |
| 52 Week Low | $35.68 | $10.65 |
| 52 Week High | $49.41 | $18.67 |
| Indicator | SLGN | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 34.95 | 68.71 |
| Support Level | $37.02 | $14.70 |
| Resistance Level | $42.75 | N/A |
| Average True Range (ATR) | 1.62 | 0.90 |
| MACD | -0.80 | 0.14 |
| Stochastic Oscillator | 6.26 | 85.09 |
Silgan Holdings Inc is a manufacturer of sustainable rigid packaging solutions for the world's essential consumer goods products. Its products include: dispensing and specialty closures for fragrance and beauty, food, beverage, personal and health care, home care and lawn and garden products; steel and aluminum containers for pet and human food and general line products; and custom designed plastic containers for pet and human food, consumer health and pharmaceutical, personal care, home care, lawn and garden and automotive products.
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.